Soluble epoxide hydrolase is an endogenous regulator of obesity-induced intestinal barrier dysfunction and bacterial translocation

Authors:

Abstract
Significance: Defective intestinal barrier function and enhanced lipopolysaccharide (LPS)/bacterial translocation is a key pathogenic factor in many human diseases, including obesity. To date, the molecular mechanisms leading to intestinal barrier defects are not well understood, and there are no available therapeutic approaches to target intestinal barrier function. Here we show that soluble epoxide hydrolase (sEH) could be a novel therapeutic target of obesity-induced intestinal barrier dysfunction and LPS/bacterial translocation, and that sEH inhibitors, which have been evaluated in human clinical trials targeting other disorders, could be promising agents for prevention or treatment.
Funding Information
  • USDA | National Institute of Food and Agriculture (2016-67017-24423)
  • USDA | National Institute of Food and Agriculture (2019-67017-29248)
  • HHS | NIH | National Cancer Institute (R03CA218520)
  • HHS | NIH | National Cancer Institute (R03CA237795)
  • USDA | National Institute of Food and Agriculture (MAS00492)
  • HHS | NIH | National Institute of Environmental Health Sciences (R35ES030443)
  • HHS | NIH | National Institute of Environmental Health Sciences (P42ES004699)
  • NSF | MPS | Division of Mathematical Sciences (1761320)
  • HHS | NIH | National Institute of Environmental Health Sciences (R00ES024806)